New Indication for Xalkori

March 22, 2016

New Indication for Xalkori

Xalkori® (crizotinib) Receives Approval for Certain NSCLC Patients

According to the medication’s prescribing information, XALKORI has received clearance from the F.D.A. for an additional indication, and is now approved to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors are ROS-1-positive. XALKORI is the first and only FDA approved treatment for patients with ROS-1-positive NSCLC.

As a limited distribution medication, XALKORI is only available from select pharmacies.  Onco360 has access and can immediately treat patients with our best-in-class service. 

Order XALKORI now.

This is the second indication for XALKORI, which is also approved for metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an F.D.A. approved test.

For more information on XALKORI please visit www.xalkori.com.